TABLE 2.
General publication characteristics (n = 705 total publications)
| Study characteristic | Percent | N |
|---|---|---|
| Study purpose(s) | ||
| Efficacy assessed | 96.6 | 681 |
| Pharmacokinetic study | 4.4 | 31 |
| Study/design features | ||
| Study 1988 or later | 94.0 | 663 |
| Randomized | 77.6 | 547 |
| Blinded | 73.3 | 517 |
| Randomized and blinded | 70.1 | 494 |
| ICHD migraine criteria used | 79.4 | 560 |
| Placebo/Sham controlled | 60.6 | 427 |
| Crossover design | 23.0 | 162 |
| Intervention information | ||
| Drug/medical device | 96.3 | 679 |
| Multiple active treatments | 36.7 | 259 |
| Open‐label study | 21.8 | 154 |
| Multiple dose levels assessed | 23.8 | 168 |